The U.S. Food and Drug Administration released long-awaited draft guidance on Aug. 27 on naming biological products, proposing that both reference products and biosimilars have nonproprietary names comprised of the core drug substance name and a different four-letter suffix.
Simplifying Global Compliance
U.S. FDA Proposes Naming Convention for Biosimilars, Reference Products
International Pharmaceutical Regulatory Monitor
